FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new conjugate of a variant of an extracellular GLP-1 receptor domain with a surfactant compound; it can be used in medicine. The invention discloses a peptide product containing polypeptide conjugated by Lys17 residue with functionalized saccharide, in an amino acid sequence of which Glu16* and Lys20* residues are cycled through their side chains to form lactam.
EFFECT: invention can be used in the treatment of non-alcoholic fat liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
10 cl, 10 ex, 9 tbl, 31 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
| SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
